Find us at #TIDESUSA 2024 this week to discuss targeted drug delivery. Our CEO Lucas Siow will be presenting unpublished in vivo data from our siRNA delivery program on May 16th.
ProteinQure’s Post
More Relevant Posts
-
Join Anna Krause during Venom Week 2024, which starts on June 5th in Durham. Anna will present the results of Phase I clinical study of Marimastat, a potent inhibitor of snake venom metalloproteinases (SVMPs) Marimastat showed excellent efficacy in in vivo models of snakebite envenoming, protecting mice from lethal doses of various venoms of viperid snakes. It has the potential to become a safe, efficient, and affordable oral drug for snakebites, protecting victims against tissue damage and hemorrhage and, ultimately, from limb amputation or even death. To the best of our knowledge, Pikralida is the only company in the world with a current regulatory dossier, GMP-quality Marimastat, and a drug product suitable for human use. Learn more about the event: https://venomweek.com/ #WHO #VenomWeek2024 #snakebites #drugdevelopment #marimastat #Pikralida
To view or add a comment, sign in
-
Zoledronic acid to prevent rebound fractures after stopping adjuvant denosumab: a randomized controlled sub-study of the ABCSG-18 trial https://lnkd.in/etCtJwvK
To view or add a comment, sign in
-
Pleased to read the exciting news from the #AAAAI24 on an exciting part of the portfolio I work on, a novel BTK inhibitor in chronic spontaneous urticaria #CSU which shows promising data from its Phase 2 readout. Read more below. #phase2 #research #development #readout #clinicalresearch #patientsafety #sanofi #chronicurticaria #immunology #inflammation
We’re presenting late-breaking data from our Phase 2 trial of a novel oral BTK inhibitor in chronic spontaneous urticaria at #AAAAI24. Learn more: https://lnkd.in/emuhvGh3
To view or add a comment, sign in
-
Anti-Tuberculosis Drugs are most frequently asked drugs during the clinical rotations. It is always hard to remember them. Here is a mnemonic for the Anti-Tuberculosis drugs and its side effects. R.I.P.E.S R: Rifampicin I: Isoniazid P: Pyrazinamide E: Ethambutol S: Streptomycin. For more helpful learning tips and mnemonics, please join #globalclinicalexintiative.
To view or add a comment, sign in
-
#Sirolimus leads to greater improvement in endothelial function in the target vessel compared to Paclitaxel after 6 months as per the Limus Flow randomized clinical trial update presented at LINC 2024. Check out this interview from Prof. Dr. Christos Rammos, MHBA highlighting the latest data of his study and the SELUTION SLR™ Drug Eluting Balloon uniqueness, which may be of benefit to most complex patients with PAD #PeripheralInterventions #PAD #CLTI #DCB #DEB #SELUTIONSLR
To view or add a comment, sign in
-
Have you heard of the Joint Access Advisory Mechanism (JAAM)? In this interview, Sanjay Bhagani, JAAM Chair, and Jacques Demotes Mainard, ECRIN Director General, discuss the origins of this mechanism to prioritise the testing of therapeutics during the COVID-19 pandemic through to its evolution in 2023. 🙌 This mechanism unites various EU funded projects including RECOVER EUROPE (REMAP-CAP), EU-RESPONSE (DisCovERY & #EUSolidACT), Ecraid Prime, and now CoMeCT project. 🤝 👉 Learn about the JAAM and how it supports clinical research: https://lnkd.in/eS-gPy9N
To view or add a comment, sign in
-
This review outlines the inotropic and chronotropic effects of various hallucinogenic drugs on the human heart.,Psychedelic Insights | Find everything from psychedelic research to implementation | Interconnected Database | Psychedelic Reports | Timely Articles
To view or add a comment, sign in
-
Executive Leadership at Sanofi. Pharmaceutical Leader with Global, Region, and Country experience in Oncology & Immunology.
Our Immunology pipeline is powering ahead. Exciting data from one of our lead assets - BTK inhibitor presented as late breaker at AAAAI. > Initiating 2 Ph3 studies in CSU and PN in 2024. > Additional data read outs expected in 2024 - Ph 3 readout in immune thrombocytopenia and Ph 2 readouts in asthma, IgG4-related disease and warm autoimmune hemolytic anemia #SanofiImmunology #miraclesofscience #ImmunologyPipeline
We’re presenting late-breaking data from our Phase 2 trial of a novel oral BTK inhibitor in chronic spontaneous urticaria at #AAAAI24. Learn more: https://lnkd.in/emuhvGh3
To view or add a comment, sign in
-
NanoViricides, Inc. (NYSE-A:NNVC) CEO Dr Anil Diwan joined Steve Darling from Proactive to share significant news regarding the successful completion of the Phase 1a/1b Clinical Trial of NV-CoV-2, targeting the treatment of COVID-19. Dr. Diwan reported that the healthy subjects participating in the clinical trial have completed their part successfully, with no adverse events reported in any of the multiple ascending dose cohorts. This outcome confirms the excellent safety profile of NV-387, the active ingredient in NV-CoV-2. All clinical trial subjects were monitored in the hospital during the treatment period, and they have since been discharged. Additionally, they have undergone the final post-discharge follow-up visit, during which no adverse events were reported. Watch at #Proactive #ProactiveInvestors #NYSEA #NNVC http://ow.ly/Jbkj105enLx
NanoViricides announces key data on Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2
proactiveinvestors.com
To view or add a comment, sign in
-
On 16 Sep in 1928, Alexander Fleming discovered penicillin, the first true antibiotic. How has drug discovery evolved since then? Share your views in Comments #didyouknow #todayinhistory #medicalhistory #vigilare #vigilarebp #vigilarebiopharma #history #medicine
To view or add a comment, sign in
5,754 followers